IA Trial Radar
Um estudo corresponde aos critérios do filtro
Visualização em cartões
Voltar à pesquisa

Development of a Shared Decision Tool to Facilitate Uptake of the Levonorgestrel-releasing Intrauterine System for the Primary Prevention of Endometrial Cancer 270 Prevenção

Em recrutamento
Os detalhes do estudo clínico estão disponíveis principalmente em inglês. No entanto, a IA Trial Radar pode ajudar! Basta clicar em 'Explicar o estudo' para visualizar e discutir as informações do estudo no idioma selecionado.
O estudo clínico NCT07382583 é um estudo observacional para Levonorgestrel, Intrauterine Systems, Prevenção, Câncer endometrial. Seu status atual é: em recrutamento. O estudo começou em 12 de fevereiro de 2026 e pretende incluir 270 participantes. Coordenado por o Centro de Câncer MD Anderson e deve ser concluído em 1 de fevereiro de 2030. Essas informações foram atualizadas no ClinicalTrials.gov em 25 de fevereiro de 2026.
Resumo
To develop an educational tool to help patients and healthcare professionals make informed decisions about endometrial cancer and available prevention options for it (such as the use of a levonorgestrel-releasing intrauterine system \[LNG-IUS\]).
Descrição detalhada
Primary Objectives

The overall goal of this study is to create a personalized decision support educational tool for the use of LNG-IUS as a primary prevention strategy for women at risk of EC. The decision support tool will not replace the consultation with a clinician. Rather, it will help prepare the participant to better understand their options and prepare them for conversations with clinicians when making a dec...

Mostrar mais
Título oficial

Development of a Shared Decision Tool to Facilitate Uptake of the Levonorgestrel-releasing Intrauterine System for the Primary Prevention of Endometrial Cancer

Condições médicas
LevonorgestrelIntrauterine SystemsPrevençãoCâncer endometrial
Outros IDs do estudo
  • 2025-1540
  • NCI-2026-00500 (Outro identificador) (NCI-CTRP Clinical Registry)
Número NCT
NCT07382583
Data de início (real)
2026-02-12
Última atualização postada
2026-02-25
Data de conclusão (estimada)
2030-02-01
Inscrição (estimada)
270
Tipo de estudo
Observacional
Status
Em recrutamento
Braços / Intervenções
Grupo de participantes/BraçoIntervenção/Tratamento
Phase 1
Identify decisional needs, patient values and experiences
Survey using a questionnaire
Patient Preference Utility Assessment and Questionnaires
Phase 2
Develop and pilot test a web-based shared medical decision tool
Survey using a questionnaire
Patient Preference Utility Assessment and Questionnaires
Desfecho primário
Medida de desfechoDescrição da medidaPrazo
Patient Utility Questionnaire
Through study completion; an average of 1 year
Assistente de participação
Critérios de elegibilidade

Idades elegíveis
Adulto, Idoso
Idade mínima
18 Years
Sexos elegíveis
Feminino

  1. Unaffected women

    1. Must be at least 18 years old
    2. Must read and speak English or Spanish
    3. Must be premenopausal
    4. Must not have a prior history of EC or complex atypical hyperplasia
    5. Must provide written, informed consent
    6. No physical, psychological, or cognitive impairments that would preclude participation in an interview as determined by the PI or study team member

  2. Affected women

    1. Must be at least 18 years old
    2. Must read and speak English or Spanish
    3. Must have a prior history of EC or complex atypical hyperplasia
    4. Must provide written, informed consent
    5. No physical, psychological, or cognitive impairments that would preclude participation in an interview as determined by the PI or study team member

  3. Healthcare Providers

    1. Physicians or advanced practice providers (physician assistants, nurse practitioners) from Family Medicine, Obstetrics & Gynecology, Internal Medicine, or Endocrinology
    2. Must be at least 18 years old
    3. Must read and speak English or Spanish
    4. Must provide written, informed consent for qualitative interviews

  • N/A
M.D. Anderson Cancer Center logoCentro de Câncer MD Anderson
Cancer Prevention Research Institute of Texas logoCancer Prevention Research Institute of Texas
Contato central do estudo
Contato: Larissa A Meyer, MD, 713-745-0973, [email protected]
2 Locais do estudo em 1 países

Texas

The Harris Health System (LBJ), Houston, Texas, 77026, United States
Larissa Meyer, MD, Contato, 281-682-8359, [email protected]
Larissa Meyer, MD, Investigador principal
Em recrutamento
MD Anderson Cancer Center, Houston, Texas, 77030, United States
Larissa A Meyer, MD, Contato, 713-745-0973, [email protected]
Larissa A Meyer, MD, Investigador principal
Em recrutamento